Our perspectives
in one place
Topic
Selected filters
Clear
News
See all156th WHO Executive Board (EB156): Individual statement on non-communicable diseases
On 4 February at the EB156 in Geneva, IFPMA delivered a statement on non-communicable diseases (NCDs).
Read moreStatement on the revision of the Declaration of Helsinki on ethical principles for medical research
On 19 October 2024, the World Medical Association (WMA) General Assembly unanimously voted to adopt a set of revisions to the Declaration of Helsinki on ethical principles for medical research.
Read moreResumed 12th session of the Intergovernmental Negotiating Body (INB 12)
On 2 December 2024 in Geneva, IFPMA delivered a statement at the resumed INB 12.
Read more
Roche Chief Executive Dr. Thomas Schinecker announced as President of global pharmaceutical industry trade association, IFPMA
Read moreINC-5 opening statement: Health industry support for a plastics instrument
On 25 November in Busan, South Korea, IFPMA, GSCF, and IGBA submitted a joint opening statement at the fifth session of the Intergovernmental Negotiating Committee (INC-5) for an international instrument to end plastics pollution.
Read moreBiopharmaceutical CEO Roundtable meets in New York, focusing on challenges and opportunities, role of pharmaceutical innovation
The Biopharmaceutical CEO Roundtable (BCR), which represents the world’s leading biopharmaceutical companies, met in New York City, on 21 November, to discuss global health challenges and public health policies impacting medical innovation. 22 November 2024, New York City – The CEOs of leading biopharmaceutical companies met in New York City to discuss collaborative solutions that...
Read morePublications
See allPharmacy-mediated substitution for biosimilars
Pharmacy-mediated substitution is a framework permitting substitution of medicines at the retail pharmacy without the consent of the prescribing physician. In this paper, IFPMA outlines a set of principles that can guide pharmacy-mediated substitution. While the principles are intended for the awareness of pharmacists, they can also relate to other healthcare providers, regulators, payers, and those involved in formulary and procurement decision-making.
Read more
Global regulatory approaches to post-approval changes in biotherapeutic products
IFPMA worked with Clarivate to study how different countries regulate post-approval changes (PACs) in biotherapeutic products. The research compared PACs guidelines across 21 countries and regions in Latin America (LATAM), Asia-Pacific (APAC), and the Middle East and Africa (MEA) to the World Health Organization (WHO) Guidelines on changes on biotherapeutic products. The findings reveal significant diversity in the level of convergence among countries and with the WHO Reference Guidelines, with a few notable trends.
Read more
#AlwaysInnovating: Pharmaceutical Industry Facts & Figures
This compendium of facts and figures aims to provide a snapshot of the contribution of the pharmaceutical industry. Pharmaceutical companies are at the forefront of developing medicines and vaccines that change how we fight and prevent disease and help solve today’s biggest health challenges. In addition to their contribution to healthier societies, pharmaceutical companies also...
Read more
Expert insights
See all
Unlocking the full value of life-course immunization: A key to sustainable healthcare
Read more
How lifelong vaccination can tackle the challenges of an ageing world
Read more
Advancing UHC through public and private sector action
Read moreResources
See allOur Ethos in Action – Decision-Making Framework Toolkit
IFPMA has developed a Five-Phase Decision-Making Framework, grounded in the IFPMA Ethos or value system, to help companies make decisions that balance business objectives and ethical considerations to meet patient needs and the expectations of the medical community, regulators, and society.
Read more
February 2024: Impact of a waiver of intellectual property rights for COVID-19 therapeutics
As discussions on an extension of a waiver of intellectual property (IP) rights on COVID-19 therapeutics continue, latest evidence and data published today explains what the adverse impact of a waiver may be on the entire innovation ecosystem and the consequences it may have on industry’s ability to fight future pandemics.
Read more
Action on NCDs: How the innovative pharmaceutical industry helps bridge the care gap
Read more